Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 8/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | TDO2 | P48775 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25812177 | 0.90 | ALOX15 (0.51) | ALOX15NUDT1BRD4IDO1TDO2 | |
| SCHEMBL23836132 | 0.90 | ALOX15 (0.52) | ALOX15NUDT1BRD4 | |
| SCHEMBL25812300 | 0.83 | ALOX15 (0.46) | ALOX15NUDT1BRD4IDO1TDO2 | |
| SCHEMBL24754422 | 0.83 | LMNA (0.51) | ALOX15NUDT1BRD4 | |
| SCHEMBL24019957 | 0.81 | ALOX15 (0.52) | ALOX15IDO1TDO2HRH4 | |
| SCHEMBL24019771 | 0.80 | ALOX15 (0.58) | ALOX15NUDT1IDO1TDO2HRH4 | |
| SCHEMBL24740100 | 0.80 | ALOX15 (0.58) | ALOX15NUDT1HRH4 | |
| SCHEMBL24020849 | 0.78 | IDO1 (0.46) | IDO1TDO2HRH4 | |
| SCHEMBL24740101 | 0.78 | ALOX15 (0.59) | ALOX15NUDT1IDO1TDO2 | |
| SCHEMBL24020852 | 0.77 | IDO1 (0.58) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ALOX15 1455/4885NUDT1 4023/4885BRD4 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.